MENU
+Compare
ETNB
Stock ticker: NASDAQ
AS OF
Apr 3, 04:59 PM (EDT)
Price
$6.88
Change
-$0.31 (-4.31%)
Capitalization
1B

ETNB 89bio Forecast, Technical & Fundamental Analysis

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases... Show more

ETNB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ETNB with price predictions
Apr 02, 2025

ETNB's RSI Indicator recovers from oversold territory

The RSI Oscillator for ETNB moved out of oversold territory on March 12, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In of the 28 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ETNB advanced for three days, in of 255 cases, the price rose further within the following month. The odds of a continued upward trend are .

ETNB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 28, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ETNB as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ETNB turned negative on March 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

ETNB moved below its 50-day moving average on March 25, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ETNB crossed bearishly below the 50-day moving average on March 10, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ETNB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ETNB entered a downward trend on March 20, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.506) is normal, around the industry mean (13.260). P/E Ratio (0.000) is within average values for comparable stocks, (64.931). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.036).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ETNB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ETNB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ETNB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ETNB is expected to report earnings to fall 48.98% to -52 cents per share on May 07

89bio ETNB Stock Earnings Reports
Q1'25
Est.
$-0.52
Q4'24
Missed
by $0.27
Q3'24
Missed
by $0.77
Q2'24
Beat
by $0.08
Q1'24
Missed
by $0.08
The last earnings report on February 27 showed earnings per share of -101 cents, missing the estimate of -75 cents. With 1.77M shares outstanding, the current market capitalization sits at 1.00B.
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
142 Sansome Street
Phone
+1 415 432-9270
Employees
70
Web
https://www.89bio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JARSX14.800.14
+0.95%
Easterly Global Real Estate R6
TIBAX27.650.02
+0.07%
Thornburg Investment Income Builder A
IARRX17.15N/A
N/A
Invesco Real Estate R
BREIX37.47N/A
N/A
Baron Real Estate Institutional
VICEX21.87N/A
N/A
USA Mutuals Vice Investor

ETNB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ETNB has been loosely correlated with AKRO. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ETNB jumps, then AKRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ETNB
1D Price
Change %
ETNB100%
+5.81%
AKRO - ETNB
58%
Loosely correlated
+8.57%
RCKT - ETNB
51%
Loosely correlated
+8.43%
IDYA - ETNB
49%
Loosely correlated
+10.70%
NTLA - ETNB
48%
Loosely correlated
+9.69%
DNLI - ETNB
47%
Loosely correlated
+11.80%
More